Reply to Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.022
Eur Urol
.
2023 Jul;84(1):7-8.
doi: 10.1016/j.eururo.2023.03.028.
Epub 2023 Apr 7.
Authors
Michael J Morris
1
,
Oliver Sartor
2
,
Johann S de Bono
3
,
Karim Fizazi
4
,
Scott T Tagawa
5
Affiliations
1
Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: morrism@mskcc.org.
2
School of Medicine, Tulane University, New Orleans, LA, USA.
3
Institute of Cancer Research and Royal Marsden Hospital, London, UK.
4
Gustave Roussy Institute, Paris-Saclay University, Villejuif, France.
5
Weill Cornell Medicine, New York, NY, USA.
PMID:
37032186
DOI:
10.1016/j.eururo.2023.03.028
No abstract available
Publication types
Editorial
Comment
MeSH terms
Dipeptides
Humans
Male
Prostate-Specific Antigen
Prostatic Neoplasms*
Prostatic Neoplasms, Castration-Resistant*
Substances
PSMA-617
Lutetium-177
Prostate-Specific Antigen
Dipeptides